Company Filing History:
Years Active: 2022
Title: Michael M Kitt: Innovating Cough Treatment with P2X3 and P2X2/3 Receptor Modulators
Introduction:
In the realm of medical advancements, innovators like Michael M Kitt are making a significant impact. Hailing from Mountain View, CA, Kitt has been pivotal in developing novel therapies for the treatment of cough and associated respiratory diseases. As an inventor and employee of Afferent Pharmaceuticals, Inc., Kitt has contributed to the field of medicine through his patented invention of diaminopyrimidine P2X3 and P2X2/3 receptor modulators. Let's delve deeper into his achievements and collaborations in the world of patents and inventions.
Latest Patents:
Michael M Kitt has a total of one patent to his name titled "Diaminopyrimidine P2X3 and P2X2/3 Receptor Modulators for use in the treatment of cough." This invention revolves around methods for treating cough, chronic cough, and urges to cough associated with respiratory diseases. By administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, Kitt's patent targets P2X3 and/or P2X2/3 receptor antagonists.
Career Highlights:
Kitt's career highlight lies in his association with Afferent Pharmaceuticals, Inc., a prominent company known for developing innovative therapies. His contributions in developing cough treatments have helped revolutionize the field of respiratory medicine, alleviating symptoms and improving the quality of life for individuals suffering from debilitating cough conditions. Kitt's dedication and expertise have undoubtedly made him a valuable asset to his team at Afferent Pharmaceuticals.
Collaborations:
Within the realm of innovative medical research, collaboration plays a crucial role. Kitt has had the privilege of working alongside notable colleagues such as Anthony P Ford and Kathleen Sereda Glaub. These collaborations have enriched Kitt's research endeavors and have likely contributed to the success of his patented invention. By joining forces with talented individuals, Kitt demonstrates the power of teamwork and collective expertise in pushing the boundaries of medical innovation.
Conclusion:
Michael M Kitt's patent on diaminopyrimidine P2X3 and P2X2/3 receptor modulators signifies his commitment to improving the treatment of cough and respiratory diseases. Through his work at Afferent Pharmaceuticals, Kitt has proven himself as a dedicated inventor and a vital contributor to groundbreaking medical advancements. As the field of medical research continues to evolve, Kitt's contributions pave the way for more effective treatments and a better quality of life for patients worldwide.